Visby gets $12M to make flu/COVID-19 self-tests

By staff writers

February 3, 2021 -- Visby Medical has received $12.3 million in U.S. government funding to speed up the development of its rapid, single-use flu/COVID-19 polymerase chain reaction (PCR) test for at-home use.

The test detects the flu and/or COVID-19 using one handheld rapid PCR test for point-of-care use. Eventually, it will be available in consumers' homes as an over-the-counter test.

The Biomedical Advanced Research and Development Authority (BARDA), an agency in the U.S. Department of Health and Human Services, awarded Visby the funds. The funding may be extended for a total of up to $48.7 million over a period of 38 months.

COVID-19 pandemic accelerates adoption of diagnostic testing at point of care
Out of a very bad year where the COVID-19 pandemic brought the world to its knees has come some good, investors say. Point-of-care diagnostics tests are...
Pathnostics debuts PCR test for COVID, flu, and RSV
Diagnostics firm Pathnostics has debuted a multiplex polymerase chain reaction (PCR) test to detect numerous respiratory ailments, including COVID-19,...
NIH, BARDA award $98.35M in COVID-19 testing contracts
The U.S. National Institutes of Health (NIH), along with the Biomedical Advanced Research and Development Authority (BARDA), a U.S. federal health agency,...
Firm developing rapid gonorrhea test wins $19M prize
A company developing a rapid diagnostic test for the microorganism that causes gonorrhea has won $19 million in a challenge that's part of the U.S....

Copyright © 2021

Last Updated ls 2/3/2021 11:41:20 AM

Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current